A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 737 participants.

Also called NCT01644500

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 737 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01644500
Other papers using this trial's data
  • A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up Journal of diabetes research, 2019 DOI, PubMed 31183384, PMC6515022 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China, South Korea, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01644500. Randomized; triple masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2015-12-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus
Acronym
AWARD-CHN1
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Dulaglutide
Intervention (Drug)
Glimepiride
Intervention (Drug)
Placebo as Capsules
Intervention (Drug)
Placebo as SC Injection
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01644500
Content hash
ff3e11d8d85aa27f5bb231f7882b5f581363d997b407ed92b828c883be7fa7d5